Targeted therapy progress of pheochromocytoma and paraganglioma
10.3760/cma.j.cn115355-20190922-00428
- VernacularTitle:嗜铬细胞瘤及副神经节瘤靶向治疗的研究进展
- Author:
Kaiyuan JIA
1
;
Xiaoming CAO
;
Keqiang YIN
;
Shaowei HAO
Author Information
1. 山西医科大学第一临床医学院，太原 030001
- From:
Cancer Research and Clinic
2020;32(7):518-521
- CountryChina
- Language:Chinese
-
Abstract:
Pheochromocytoma and paraganglioma are rare neuroendocrine tumors. Because of the abnormal secretion of catecholamine, the risk of disease is high. At present, the choice of drug treatment for these diseases is still controversial. The further understanding of the research has showed that the different molecular subtypes have different carcinogenic mechanism and therapeutic response. And a variety of corresponding targeted drugs have entered the clinical trial stage, showing a certain therapeutic potential. This article reviews the current treatment and the progress of targeted drugs for pheochromocytoma and paraganglioma.
